Drotaverine Reneval, tablets 40 mg 28 pcs

A myotropic antispasmodic, isoquinoline derivative. By chemical structure and pharmacological properties it is similar to papaverine, but has a stronger and longer action. It reduces influx of calcium ions into smooth muscle cells (inhibits phosphodiesterase, leads to accumulation of intracellular cyclic adenosine monophosphate).

Reduces smooth muscle tone of internal organs and intestinal peristalsis, dilates blood vessels. It does not influence vegetative nervous system. It does not influence central nervous system.

Presence of direct influence on smooth muscles allows to use it as an antispasmodic when drugs from m-cholinoblocker group are contraindicated (closed-angle glaucoma, prostatic hyperplasia).

Pharmacokinetics

When administered orally the absorption is high, period of semi-absorption – 12 min. Bioavailability – 100%. Evenly distributed in tissues, penetrates into smooth muscle cells. Maximal concentration in blood plasma is 2 hours. Plasma protein binding is 95-98%. It is mainly excreted by kidneys, to a lesser extent – with bile. Does not penetrate the blood-brain barrier.

Indications

Gastroduodenitis, Colic, Pain, Threatened miscarriage, Gallic colic, Cholecystitis, Renal colic, Colitis, Bloating, Painful menstruation, Enteritis, Gallstone disease, Gastritis, Headache, Peptic ulcer, Urinary stone diseaseSpasm of smooth muscles in diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, inflammation of the papilla of the 12 duodenum.

Smooth muscle spasm in diseases of the urinary tract: nephrourolithiasis, urethrolithiasis, pyelitis, cystitis, bladder spasm.

As adjuvant therapy: in spasms of the smooth muscles of the gastrointestinal tract: Gastric and 12 duodenal ulcer, gastritis, cardiac and gateway spasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome with flatulence; tensor headache; algodysmenorrhea, threatened miscarriage, threatened premature labor; uterine cervix spasm during labor, prolonged opening of the cervix, postpartum contractions.

In some instrumental studies, including cholecystography.

Active ingredient

Drotaverine

Composition

The active substance:
Drotaverine hydrochloride – 0,04 g
Excipients:
lactose monohydrate (milk sugar) – 0,0700 g
potato starch – 0,0216 g
povidone K-30 – 0,0042 g
crosspovidone – 0,0014 g
talc – 0,0014 g
magnesium stearate – 0,0014 g

How to take, the dosage

Adults, oral 40-80 mg (1-2 tablets) 2-3 times a day.
Children, oral at the age of 3-6 years – 40-120 mg in 2-3 receptions, the maximum daily dose – 120 mg, 6-18 years – 80-200 mg in 2-5 receptions, the maximum daily dose – 240 mg.

Interaction

When used concomitantly, drotaverine may weaken the antiparkinsonian effect of levodopa. It enhances the effect of papaverine, bendazole and other antispasmodics (including m-cholinoblockers), decrease in blood pressure caused by tricyclic antidepressants, quinidine and procainamide.
Phenobarbital increases the spasmolytic effect of drotaverine. It reduces the antispasmodic activity of morphine.

Special Instructions

During treatment, it is necessary to refrain from driving and engaging in other potentially dangerous activities that require high concentration and quick psychomotor reactions.

Contraindications

Hypersensitivity to the components of the drug, expressed hepatic, renal failure, lactation, children under 3 years of age, galactose intolerance, lactase deficiency, glucose-galactose malabsorption.

With caution

Severe atherosclerosis of the coronary arteries, prostatic hyperplasia, closed-angle glaucoma, pregnancy.

Side effects

Dizziness, headache, insomnia, palpitations, tachycardia, fever, increased sweating, nausea, constipation, decreased blood pressure, allergic skin reactions, angioedema, urticaria, rash, itching.

Overdose

Symptoms: excessive doses disrupt atrial-ventricular conduction, reduce excitability of the heart muscle, may cause cardiac arrest and respiratory center depression.
Treatment: the patient should be under close medical supervision and receive symptomatic and supportive treatment. Induction of vomiting and/or gastric lavage is recommended.

Pregnancy use

Controlled studies in pregnant women have not been conducted, but the potential benefits may justify the use of drotaverine for the mother, despite the possible risk to the fetus. Contraindicated during breastfeeding.

Similarities

No-shpa, Drotaverine, Spasmonet, Drotaverine-Teva